Drug intelligence / Profile preview

pyrimethamine

Development stage: Approved
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Pyrimethamine is an antiparasitic medication primarily used to treat and prevent toxoplasmosis and other parasitic infections. It works as a folic acid antagonist by inhibiting dihydrofolate reductase, which blocks the biosynthesis of purines and pyrimidines essential for DNA synthesis and cell multiplication in parasites. This mechanism prevents parasites from growing and reproducing in the body. Pyrimethamine is typically administered with a sulfonamide and folinic acid to enhance effectiveness and reduce side effects.

Brand names: DaraprimFansidar
Other names: pyrimethamine

Targets

FOLR1 (FRα)DHFR (Dihydrofolate reductase)DHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)HEXB (Beta-hexosaminidase subunit beta)

Beyond the preview

Go deeper on pyrimethamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pyrimethamine.

Explore the full profile